Quarterly report · Q2
9265.TEDINET S100SKGJ
Period2023-06-01 → 2023-11-30
Filed2024-01-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥28.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Revenue | ¥58.2bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥27.7bn | 2022-06-01 → 2022-11-30 | Cons. | Net sales |
| Operating income | ¥618m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Operating income | ¥598m | 2022-06-01 → 2022-11-30 | Cons. | Operating income |
| Ordinary income | ¥645m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥624m | 2022-06-01 → 2022-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥700m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥20m | 2022-06-01 → 2022-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥480m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥219m | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥201m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥477m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Net income | −¥204m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss |
| Total assets | ¥24.8bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥24.6bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥22.9bn | at 2022-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥16.5bn | at 2023-11-30 | Cons. | Liabilities |
| Total liabilities | ¥16.6bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.3bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.6bn | at 2022-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.0bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.8bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.0bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2022-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥544m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.2bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.9bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥154m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥107m | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥88m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥123m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥209m | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥209m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥188.05 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥124.52 | 2023-09-01 → 2023-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.83 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-78.98 | 2022-06-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-143.68 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 33.5% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.2% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2023-11-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥494m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥146m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥146m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥6m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥28.7bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥28.7bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥1.1bn |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥36m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥36m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥2m |
| —segment total | revenue | 2023-06-01 → 2023-11-30 | ¥28.9bn |
| —segment total | revenue external | 2023-06-01 → 2023-11-30 | ¥28.9bn |
| —segment total | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| —segment total | segment profit | 2023-06-01 → 2023-11-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2022-11-30 | −¥11m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2022-11-30 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2022-11-30 | −¥447m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥140m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥140m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥3m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥27.5bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥27.5bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥11m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥1.0bn |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥33m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥33m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥0 |
| —segment total | revenue | 2022-06-01 → 2022-11-30 | ¥27.7bn |
| —segment total | revenue external | 2022-06-01 → 2022-11-30 | ¥27.7bn |
| —segment total | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥11m |
| —segment total | segment profit | 2022-06-01 → 2022-11-30 | ¥1.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 490
| Item | Context | Value | Unit |
|---|---|---|---|
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社（信託口） | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)東京都港区浜松町２丁目11番３号 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)小沼 滋紀 | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)千葉県野田市 | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)株式会社十八親和銀行 | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)長崎県長崎市銅座町１番11号 | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)山下 浩 | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)長崎県佐世保市 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)ヤマシタヘルスケアホールディングス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)福岡県福岡市博多区下川端町２番１号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding reversal of allowance for doubtful accounts (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding receipts from contingent consideration (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding provision of allowance for doubtful accounts (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |